Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Hypercholesterolemia in the U.S.

Analysis of: FDA Gives Go-Ahead to Once-Daily Valsartan-Amlodipine Combination Pill for Hypertension (www.medscape.com)
ExForge is a product that we in the hypertension business are very anxious to have available. Combination tablets have been increasing in sales very dramatically in the past few years and will soon overtake, in my opinion, single agents. Lotrel led the way toward combinations that do not include a diuretic...
Analysis of: FDA Gives Go-Ahead to Once-Daily Valsartan-Amlodipine Combination Pill for Hypertension (www.medscape.com)
Newly introduced guidelines for treatment targets in hypertensive patients target lower blood pressures than  those previously suggested by JNC.  Since it has already been demonstrated that control of BP to current targets in many hypertensives requires three or more drugs, even lower targets...
July 6, 2007
Your wallet.
Analysis of: When patients pay more, they use less medicine, study finds (www.tennessean.com)
When patients are aware of cost, in general it is a good thing.
July 6, 2007
Shocking? Not!!!!
Analysis of: Humana, UnitedHealth Suspend Some Health Plans After Complaints (www.bloomberg.com)
The insurance industry and its agents are one of the most fraud laden industries around.
July 6, 2007
It's about time
Analysis of: FDA OKs Dietary Supplement Regulations (www.webmd.com)
Long overdue regulation of dietary supplements. Some if not all of the claims that companies make need to be stopped.
July 6, 2007
Typical deception
Analysis of: New Vioxx Study May Cast Doubt On Merck Claims (online.wsj.com)
The article is not surprising. Most pharmaceutical companies will on pull drug off the market until the public stops using it or doctors stop prescibing the medication.
Analysis of: Pfizer’s Lyrica Receives FDA Approval for Fibromyalgia (home.businesswire.com)
Something actually indicated for this disease.
Analysis of: Shire Receives Approvable Letter from FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD (www.pipelinereview.com)
Alternative drug to use.  Lower abuse potential  Lower stigma
Analysis of: The U.S. Food and Drug Administration Approves New Actonel Dose to Treat and Prevent Postmenopausal Osteoporosis (phx.corporate-ir.net)
Compliance issues  ? side effects
June 20, 2007
Cephalon BUNK
Analysis of: Cephalon Receives FDA Approval of NUVIGIL(TM) for the Treatment of Excessive Sleepiness Associated with Three Disorders (www.pipelinereview.com)
Gee whiz, so Cephalon had isolated the enantiomer of provigil that is effetcive. This is the equivalent to AZ isoloating the s enantiomer of ompeprazole to create Nexium and lord ir over prilosec. This is no great feat chemically or pharmacologiclly. What it may mean is millions in profits for investors....

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next81 to 90 of 146

Analytics


Generated at 2009-01-07T19:00:58.307